Advances in Host and Vector Development for the Production of Plasmid DNA Vaccines

• DOI: 10.1007/978-1-4939-0345-0_38
• Publication Date: 2014-02-21T15:40:30Z
• Authors: Juergen Mairhofer; Alvaro R. Lara
• Keywords: Genetic Vectors; Temperature; Anti-Bacterial Agents; Social Control, Formal; 3. Good health; Metabolic Engineering; Fermentation; Escherichia coli; Vaccines, DNA; Gene Silencing; Transgenes; Safety; Genetic Engineering; Plasmids

Recent developments in DNA vaccine research provide a new momentum for this rather young and potentially disruptive technology. Gene-based vaccines are capable of eliciting protective immunity in humans to persistent intracellular pathogens, such as HIV, malaria, and tuberculosis, for which the conventional vaccine technologies have failed so far. The recent identification and characterization of genes coding for tumor antigens has stimulated the development of DNA-based antigen-specific cancer vaccines. Although most academic researchers consider the production of reasonable amounts of plasmid DNA (pDNA) for immunological studies relatively easy to solve, problems often arise during this first phase of production. In this chapter we review the current state of the art of pDNA production at small (shake flasks) and mid-scales (lab-scale bioreactor fermentations) and address new trends in vector design and strain engineering. We will guide the reader through the different stages of process design starting from choosing the most appropriate plasmid backbone, choosing the right Escherichia coli (E. coli) strain for production, and cultivation media and scale-up issues. In addition, we will address some points concerning the safety and potency of the produced plasmids, with special focus on producing antibiotic resistance-free plasmids. The main goal of this chapter is to make immunologists aware of the fact that production of the pDNA vaccine has to be performed with as much as attention and care as the rest of their research.